Key Takeaways
- • Ares Management closed its inaugural Ares Specialty Healthcare Fund (ASH) at approximately $1.5 billion in capital, inclusive of anticipated leverage, marking a significant commitment to direct lending in the healthcare sector.
- • The Fund deploys flexible capital across five specialized healthcare sub-sectors: pharmaceuticals and biotechnology, medical technologies, tools and diagnostics, specialty services, and healthcare IT, targeting both sponsored and non-sponsored companies globally.
- • ASH provides multiple investment structures including first lien, second lien, mezzanine, preferred equity, and non-control equity opportunities, positioning Ares to capture opportunities across the healthcare credit spectrum.
- • Proskauer's multidisciplinary team managed complex regulatory, tax, and fund structuring requirements, reflecting the cross-functional expertise required for large-scale alternative investment fund launches in highly regulated sectors.
Summary
Ares Management Corporation, the NYSE-listed alternative investment manager, has successfully closed its inaugural Ares Specialty Healthcare Fund (ASH) with approximately $1.5 billion in capital raised, inclusive of anticipated leverage. The completion represents a strategic expansion of Ares Direct Lending's platform into dedicated healthcare-focused lending and represents the final close of the Fund as of November 5, 2025.
The Fund is structured to provide flexible capital solutions to specialty healthcare companies—both sponsored and non-sponsored—through a diversified array of investment instruments. ASH's mandate spans directly originated first lien, second lien, mezzanine, preferred equity, and non-control equity opportunities. The strategy targets public and private companies across five core sub-sectors: pharmaceuticals and biotechnology, medical technologies, tools and diagnostics, specialty services, and healthcare IT. This multi-sector, multi-structure approach allows Ares to address capital needs across the healthcare ecosystem on a global basis.
The complexity of the transaction required coordinated legal expertise across multiple disciplines. Proskauer Rose LLP advised Ares on the fundraise, with the engagement directed by partner N. Carter Noon and associates Alicia Abboud, Mark Cricco, and Nikita Patel from the Private Investment Funds practice. Tax matters were handled by partner David Miller alongside associates Sean Webb and Maggie Livingstone. Regulatory oversight was managed by partners Robert Sutton and Nathan Schuur, with additional support from partner Adam Scoll (Compensation & Benefits) and associates Andrew Park and Brendan Conroy. This integrated approach underscores the regulatory and tax complexities inherent in launching a specialized healthcare credit vehicle at scale.
The ASH Fund represents Ares Direct Lending's focused entry into healthcare credit, a sector where specialized knowledge of reimbursement dynamics, regulatory requirements, and cash flow stability can differentiate returns. The $1.5 billion raise signals institutional investor confidence in Ares' healthcare expertise and positions the manager to compete in a space where dedicated, sector-focused lending has attracted significant capital flows from both traditional and alternative capital sources.
The Fund is structured to provide flexible capital solutions to specialty healthcare companies—both sponsored and non-sponsored—through a diversified array of investment instruments. ASH's mandate spans directly originated first lien, second lien, mezzanine, preferred equity, and non-control equity opportunities. The strategy targets public and private companies across five core sub-sectors: pharmaceuticals and biotechnology, medical technologies, tools and diagnostics, specialty services, and healthcare IT. This multi-sector, multi-structure approach allows Ares to address capital needs across the healthcare ecosystem on a global basis.
The complexity of the transaction required coordinated legal expertise across multiple disciplines. Proskauer Rose LLP advised Ares on the fundraise, with the engagement directed by partner N. Carter Noon and associates Alicia Abboud, Mark Cricco, and Nikita Patel from the Private Investment Funds practice. Tax matters were handled by partner David Miller alongside associates Sean Webb and Maggie Livingstone. Regulatory oversight was managed by partners Robert Sutton and Nathan Schuur, with additional support from partner Adam Scoll (Compensation & Benefits) and associates Andrew Park and Brendan Conroy. This integrated approach underscores the regulatory and tax complexities inherent in launching a specialized healthcare credit vehicle at scale.
The ASH Fund represents Ares Direct Lending's focused entry into healthcare credit, a sector where specialized knowledge of reimbursement dynamics, regulatory requirements, and cash flow stability can differentiate returns. The $1.5 billion raise signals institutional investor confidence in Ares' healthcare expertise and positions the manager to compete in a space where dedicated, sector-focused lending has attracted significant capital flows from both traditional and alternative capital sources.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.